Top

16-09-2017 | Multiple myeloma | Article

Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study

Journal: Supportive Care in Cancer

Authors: Matthias Naegele, Monika Kirsch, Gabriele Ihorst, Katharina Fierz, Monika Engelhardt, Sabina De Geest

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

High-dose melphalan and autologous stem cell transplantation (ASCT) are associated with high symptom burden. This study aimed to explore multiple myeloma (MM) patients’ experience of symptom frequency, intensity, and distress during therapy.

Methods

This descriptive longitudinal study enrolled 29 MM patients who completed the 43-item PROVIVO questionnaire, measuring symptom experience across the dimensions of frequency, intensity, and distress at four assessment points: hospital admission (T0), leucocyte nadir (T1), discharge (T2), and 30 days post discharge (T3). Symptom assessment covered five categories: (1) physical, (2) emotional, (3) cognitive, (4) male/female urogenital symptoms, and (5) follow-up care planning (e.g., financial problems). Results were displayed as heat maps and bubble graphs for each patient, differences between T0 and T4 individually assessed, and intensity (IMS) and mean distress scores (DMS) calculated on a scale from 0 to 4.

Results

The most frequent, intense, and distressing physical symptoms were fatigue, diarrhea, and decreased appetite. As expected, peak symptom intensity (decreased appetite 2.79) and distress (diarrhea 2.11) were reported during high-dose melphalan and the leucocyte nadir (T1). Thereafter, most symptoms’ intensity and distress improved. Items on urogenital symptoms remained predominantly unanswered or patients were sexually inactive.

Conclusions

PROVIVO enabled exploration of various dimensions of MM patients’ symptom experiences, which differed substantially before and after ASCT. Our results suggest that high-dose melphalan, ASCT, and other intensive novel agent therapies warrant targeted symptom management programs that include focused patient support.

Moreau P et al (2013) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi133–vi137CrossRefPubMed

Deutsches Register für Stammzelltransplantationen. Jahresbericht 2011. 2011 14.11.2011]; Available from: http://www.drst.de/download/jb2010.pdf

Cavo M et al (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117(23):6063–6073CrossRefPubMedPubMedCentral

Engelhardt M et al (2010) Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 51(8):1424–1443CrossRefPubMed

Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360(25):2645–2654CrossRefPubMed

Anderson KO et al (2007) Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 39(12):759–766CrossRefPubMed

Campagnaro E et al (2008) Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 112(7):1617–1624CrossRefPubMed

Larsen J et al (2003) Symptom distress, functional status and health-related quality of life before high-dose chemotherapy with stem-cell transplantation. Eur J Cancer Care 12(1):71–80CrossRef

Larsen J et al (2004) Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation. Cancer Nurs 27(1):55CrossRefPubMed

10.

Larsen J et al (2007) Factors associated with poor general health after stem-cell transplantation. Support Care Cancer 15(7):849–857CrossRefPubMed

11.

Andersson I et al (2008) Health related quality of life in stem cell transplantation: clinical and psychometric validation of the questionnaire module, high dose chemotherapy (HDC-19). Acta Oncol 47(2):275–285CrossRefPubMed

12.

Gulbrandsen N et al (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18(1):65–77CrossRefPubMed

13.

Sherman AC et al (2003) Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. Support Care Cancer 11(9):568–574CrossRefPubMed

14.

Diez-Campelo M et al (2004) Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. Bone Marrow Transplant 34(8):729–738CrossRefPubMed

15.

Sherman AC et al (2004) Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 33(9):955–962CrossRefPubMed

16.

Uyl-de Groot CA et al (2005) Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 74(2):136–143CrossRefPubMed

17.

Sherman AC et al (2009) Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 15(1):12–20CrossRefPubMed

18.

Armstrong TS (2003) Symptoms experience: a concept analysis. Oncol Nurs Forum 30(4):601–606CrossRefPubMed

19.

Williams LA et al (2014) Symptom burden of busulfan + melphalan versus melphalan alone for multiple myeloma. Blood 124(21):1277–1277

20.

Cohen MZ et al (2012) Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. J Pain Symptom Manag 44(2):168–180CrossRef

21.

Jones D et al (2013) Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 6:13CrossRefPubMedPubMedCentral

22.

Wang XS et al (2014) Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366–1374CrossRefPubMedPubMedCentral

23.

Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed

24.

U.S. Department of Health and Human Services, National Institutes of Health, and N.C. Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2010 04.12.2015]; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

25.

Berger D et al (2009) Das Blaue Buch: Chemotherapie-Manual Hämatologie und Onkologie, 3rd edn. Springer, Berlin

26.

Basch E et al (2007) Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25(34):5374–5380CrossRefPubMed

27.

Basch E et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632CrossRefPubMedPubMedCentral

28.

Knop S et al (2014) Response to lenalidomide, doxorubicin and dexamethasone (RAD) in newly diagnosed multiple myeloma is independent of cytogenetic risk and retained after double stem cell transplant. Blood 124(21):177–177

29.

Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet 385(9983):2197–2208CrossRefPubMed

30.

Engelhardt M et al (2016) Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica

31.

Straka C et al (2016) Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica 101(11):1398–1406CrossRefPubMedPubMedCentral

32.

Greipp PR et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420CrossRefPubMed

33.

Mor V et al (1984) The Karnovsky Performance Status Scale. An examination of its reliability and validity in research setting. Cancer 53:2002–2007CrossRefPubMed

34.

Svahn B et al (2000) Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. Bone Marrow Transplant 26(10):1057–1060CrossRefPubMed

35.

Kirsch M et al (2015) Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. Eur J Oncol Nurs 19(1):66–74CrossRefPubMed

36.

Harousseau J, Dreyling M (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v155–v157CrossRefPubMed

37.

Lanuza DM et al (2012) A longitudinal study of patients’ symptoms before and during the first year after lung transplantation. Clin Transpl 26(6):E576–E589CrossRef

38.

Jim HS, Syrjala KL, Rizzo D (2012) Supportive care of hematopoietic cell transplant patients. Biol Blood Marrow Transplant 18(1 Suppl):S12–S16CrossRefPubMedPubMedCentral

39.

Snowden JA et al (2011) Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154(1):76–103CrossRefPubMed

40.

Gibson RJ et al (2013) Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 21(1):313–326CrossRefPubMed

41.

Terpos, E., et al., European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica, 2015. 100(10): p. 1254–1266

42.

Peterson DE et al (2013) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 21(1):327–332CrossRefPubMed

43.

Phillips D, Clancy K (1972) Some effects of “social desirability” in survey studies. Am J Sociol 77(5):921–940CrossRef

44.

Stephens M (2005) The lived experience post-autologous haematopoietic stem cell transplant (HSCT): a phenomenological study. Eur J Oncol Nurs 9(3):204–215CrossRefPubMed